title: Conditional Approval Pathways: The "Special" Case of Global Regenerative Medicine Regulation.
authors.affiliation: 1 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford , Oxford, United Kingdom .|2 The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), University of Oxford , Oxford, United Kingdom .
authors.forename: James A
authors.initials: JA
authors.lastname: Smith
authors.affiliation: 1 Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, Nuffield Orthopaedic Centre, University of Oxford , Oxford, United Kingdom .|2 The Oxford-UCL Centre for the Advancement of Sustainable Medical Innovation (CASMI), University of Oxford , Oxford, United Kingdom .|3 Harvard Stem Cell Institute, Harvard University , Cambridge, Massachusetts.|4 Department of Paediatrics, University of Oxford , Oxford, United Kingdom .|5 Centre for Behavioural Medicine, UCL School of Pharmacy, University College London , London, United Kingdom .|6 Stanford-UCSF FDA Centre for Regulatory Science and Innovation , San Francisco, California.
authors.forename: David A
authors.initials: DA
authors.lastname: Brindley
mesh_terms: D005060:Europe; D006801:Humans; D007564:Japan; D044968:Regenerative Medicine / Q000331:legislation & jurisprudence*; D012926:Social Control, Formal; D014481:United States; D014486:United States Food and Drug Administration